{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:16:07Z","timestamp":1773342967806,"version":"3.50.1"},"reference-count":17,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kranus Health GmbH","award":["2210,00 CHF"],"award-info":[{"award-number":["2210,00 CHF"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The BEST study investigated the effectiveness of a 12-week digital treatment program for male LUTS. Here, we report on the long-term outcomes of the patients involved in this trial. Methods: The randomized controlled BEST trial enrolled 237 patients (intervention group, IG: n = 112, hereafter referred to as the direct intervention group [DIG]; control group, CG: n = 125, hereafter referred to as the postponed intervention group [PIG]). The intervention consisted of pelvic floor muscle training, behavioral training, completion of a micturition diary, bladder training, urge suppression techniques, fluid and dietary management, and structured educational content. Patients in the DIG received the intervention immediately, Patients in the PIG after a 12-week waiting period. Patients in both groups were offered the option to complete additional treatment cycles at their discretion. The primary endpoint was change from baseline in the International Prostate Symptom Score (IPSS). Secondary endpoints included the symptom severity (OAB-q SF1) and quality-of-life (OAB-q SF2) subscales of the Overactive Bladder Questionnaire, among others. Long-term follow-up assessments at 24, 36, and 48 weeks for participants in both study arms were prospectively specified in the study protocol. Results: Baseline data from 236 patients were available for the follow-up analyses. In a linear mixed-effects model, the fixed effect of time on IPSS was found to be statistically significant (F(4, 515.245) = 89.77, p &lt; 0.001), indicating differences across measurement time points. Compared with the baseline, IPSS scores were lower at all subsequent follow-up assessments. The mean difference between the baseline and 12 weeks after was \u22126.32 points (95% CI: \u22127.60 to \u22125.04; p &lt; 0.001). Differences between the baseline and 24 weeks (\u22127.81 points; 95% CI: \u22129.37 to \u22126.25; p &lt; 0.001), baseline and 36 weeks (\u22128.62 points; 95% CI: \u221210.46 to \u22126.79; p &lt; 0.001), and baseline and 48 weeks (\u22129.56 points; 95% CI: \u221212.66 to \u22126.46; p &lt; 0.001) were also statistically significant. Comparable patterns of improvement were observed for both subscales of the OAB-q Short Form questionnaire. In a separate linear mixed-effects model, the fixed effect of time on IPSS after the discontinuation of app usage was not statistically significant (F(2, 19.750) = 0.01, p = 0.992), suggesting stable effects after discontinuation. Conclusions: Long-term outcomes of the structured app-based therapeutic program demonstrated that a multimodal digital intervention for male LUTS induces a rapid and clinically meaningful symptom reduction within the first 12 weeks, with consolidating and sustaining benefits over up to 48 weeks.<\/jats:p>","DOI":"10.3390\/jcm15062128","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:43:27Z","timestamp":1773225807000},"page":"2128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital Therapy for Male LUTS: Results After Mid- and Longterm Follow-Up"],"prefix":"10.3390","volume":"15","author":[{"given":"Erik","family":"Krieger","sequence":"first","affiliation":[{"name":"Charit\u00e9, Department of Urology, University of Berlin, 10117 Berlin, Germany"},{"name":"Department of Clinical Research, Kranus Health, 80331 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[{"name":"Charit\u00e9, Department of Urology, University of Berlin, 10117 Berlin, Germany"},{"name":"Department of Clinical Research, Kranus Health, 80331 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Patrick","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Kranus Health, 80331 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-8312","authenticated-orcid":false,"given":"Laura","family":"Wiemer","sequence":"additional","affiliation":[{"name":"Charit\u00e9, Department of Urology, University of Berlin, 10117 Berlin, Germany"},{"name":"Department of Clinical Research, Kranus Health, 80331 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-263X","authenticated-orcid":false,"given":"Sandra","family":"Sch\u00f6nburg","sequence":"additional","affiliation":[{"name":"BG Klinikum Bergmannstrost, 06112 Halle (Saale), Germany"},{"name":"Department of Urology and Kidney Transplantation, Martin Luther University, 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/a-2573-7302","article-title":"Digital health for benign prostate syndrome","volume":"56","year":"2025","journal-title":"Aktuelle Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"EVIDoa2400290","DOI":"10.1056\/EVIDoa2400290","article-title":"A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract Symptoms","volume":"4","author":"Gratzke","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00345-025-06016-2","article-title":"Evaluating the impact of digital therapy for male LUTS: Insights from the BEST trial subgroup analysis","volume":"43","author":"Wiemer","year":"2025","journal-title":"World J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70069","DOI":"10.1002\/bco2.70069","article-title":"Differential impact of digital therapy on storage and voiding LUTS: A post-hoc IPSS analysis from the BEST randomized controlled trial","volume":"6","author":"Gratzke","year":"2025","journal-title":"BJUI Compass"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Barry, M.J., Fowler, F.J., O\u2019leary, M.P., Bruskewitz, R.C., Holtgrewe, H.L., Mebust, W.K., Cockett, A.T., and The Measurement Committee of the American Urological Association (1992). The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol., 148.","DOI":"10.1016\/S0022-5347(17)36966-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual. Life Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euros.2025.09.003","article-title":"Defining the Minimal Important Difference in International Prostate Symptom Score for Men with Lower Urinary Tract Symptoms Using a Patient-centered Anchor Measure","volume":"81","author":"Wiemer","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/nau.23593","article-title":"Design of programs to train pelvic floor muscles in men with urinary dysfunction: Systematic review","volume":"37","author":"Hall","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.39010.551319.AE","article-title":"Self management for men with lower urinary tract symptoms: Randomised controlled trial","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1370\/afm.2609","article-title":"Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis","volume":"19","author":"Albarqouni","year":"2021","journal-title":"Ann. Fam. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1464-410X.2009.08497.x","article-title":"The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures","volume":"104","author":"Yap","year":"2009","journal-title":"BJU Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.urology.2011.11.091","article-title":"The potential role of a self-management intervention for benign prostate hyperplasia","volume":"79","author":"Chen","year":"2012","journal-title":"Urology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/j.1532-5415.2011.03724.x","article-title":"Behavioral versus drug treatment for overactive bladder in men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial","volume":"59","author":"Burgio","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamainternmed.2019.6398","article-title":"Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial","volume":"180","author":"Burgio","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/iju.13339","article-title":"Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial","volume":"24","author":"Hut","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0197-2456(02)00263-5","article-title":"Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial","volume":"24","author":"Bautista","year":"2003","journal-title":"Control. Clin. Trials"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:13:16Z","timestamp":1773310396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15062128"],"URL":"https:\/\/doi.org\/10.3390\/jcm15062128","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}